Forgotten but not gone: New developments in the understanding and treatment of tardive dyskinesia

CNS Spectrums

Volumn 21, Issue S1, 2016, Pages 16-23

  Meyer, Jonathan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Department of State Hospitals (DSH)   (United States)

Author keywords

antipsychotic; gingko; Key words Amantadine; tardive dyskinesia; tetrabenazine

Indexed keywords

AMANTADINE; CLONAZEPAM; DEUTETRABENAZINE; DOPAMINE 2 RECEPTOR; GINKGO BILOBA EXTRACT; OLANZAPINE; PLACEBO; QUETIAPINE; TETRABENAZINE; VALBENAZINE; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2; ADRENERGIC RECEPTOR AFFECTING AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PLANT EXTRACT; VALINE;

ANTIOXIDANT ACTIVITY; BINDING AFFINITY; BINDING SITE; BRAIN DEPTH STIMULATION; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNEURON; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PALLIDOTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SOMNOLENCE; TARDIVE DYSKINESIA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED;

ADRENERGIC UPTAKE INHIBITORS; AMANTADINE; ANTIPSYCHOTIC AGENTS; CLONAZEPAM; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; GABA MODULATORS; HUMANS; PLANT EXTRACTS; RISK FACTORS; TARDIVE DYSKINESIA; TETRABENAZINE; VALINE;

EID: 85008515608     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852916000730     Document Type: Review

References (54)

1. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016; 76(7): 759-777.
2. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016; 76(7): 779-787.
3. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013; 13(1): 152-160.
4. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000; 61(Suppl 4): 10-14.
5. Koning JPF, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull. 2010; 36(4): 723-731.
6. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014; 11(1): 166-176.
7. Ryu S, Yoo JH, Kim JH, et al. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a crosssectional and retrospective study. J Clin Psychopharmacol. 2015; 35(1): 13-21.
8. Kinon BJ, Kollack-Walker S, Jeste D, et al. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol. 2015; 28(1): 67-79.
9. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012; 27(10): 1205-1215.
10. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther. 2013; 7(6): 1329-1340.
11. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S113-S117.
12. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000; 61(Suppl 4): 5-9.
13. Mahmoudi S, Levesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord. 2014; 29(9): 1125-1133.
14. Segman RH, Goltser T, Heresco-Levy U, et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J. 2003; 3(5): 277-283.
15. Le Foll B, Wilson AA, Graff A, Boileau I, Di Ciano P. Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. Front Pharmacol. 2014; 5(1): 161.
16. Son WY, Lee HJ, Yoon HK, et al. Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia. Nord J Psychiatry. 2014; 68(2): 123-128.
17. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics. 2008; 18(4): 317-323.
18. Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res. 2013; 47(11): 1760-1765.
19. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull. 1995; 31(1): 159-165.
20. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003; 17(1): 47-62.
21. Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46(1): 207-213.
22. An HM, Tan YL, Shi J, et al. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr Res. 2015; 162(1-3): 261-268.
23. Grover S, Kumar P, Singh K, Vikram V, Budhiraja RD. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)-alpha and gamma agonist against a rat model of oral dyskinesia. Pharmacol Biochem Behav. 2013; 111(1): 17-23.
24. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004; 65(1): 92-96.
25. Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016; 86(7): 651-659.
26. Sarró S, Pomarol-Clotet E, Canales-Rodríguez EJ, et al. Structural brain changes associated with tardive dyskinesia in schizophrenia. Br J Psychiatry. 2013; 203(1): 51-57.
27. Zhang XY, Xiu MH, Chen da C, et al. Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J Psychiatr Res. 2010; 44(7): 429-433.
28. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5): 463-469.
29. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001;(4): CD000209.
30. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990; 147(4): 445-451.
31. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997; 17(2): 88-91.
32. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010; 33(6): 271-275.
33. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(5): 615-621.
34. Chandler JH. Reserpine in the treatment of Huntington's chorea. Med Bull (Ann Arbor). 1955; 21(4): 95-100.
35. Lazarte JA, Petersen MC, Baars CW, et al. Huntington's chorea: results of treatment with reserpine. Proc Staff Meet Mayo Clin. 1955; 30(16): 358-365.
36. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959; 127: 103-109.
37. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972; 27(1): 95-99.
38. Scherman D, Weber MJ. Characterization of the vesicular monoamine transporter in cultured rat sympathetic neurons: persistence upon induction of cholinergic phenotypic traits. Dev Biol. 1987; 119(1): 68-74.
39. Roghani A, Feldman J, Kohan SA, et al. Molecular cloning of a putative vesicular transporter for acetylcholine. Proc Natl Acad Sci U S A. 1994; 91(22): 10620-10624.
40. Erickson JD, Eiden LE, Schafer MK, Weihe E. Reserpine-and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter. J Mol Neurosci. 1995; 6(4): 277-287.
41. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996; 93(10): 5166-5171.
42. Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995; 278(3): 249-252.
43. Kilbourn MR, Lee LC, Heeg MJ, Jewett DM. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality. 1997; 9(1): 59-62.
44. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013; 28(2): 210-215.
45. Muller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015; 24(6): 737-742.
46. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011; 11(11): 1509-1523.
47. SEC Form S-1 Registration Statement of Auspex Pharmaceuticals, Inc. December 20, 2013. https://www.sec.gov/Archives/edgar/data/1454189/000119312513481239/d627086ds1.htm. Accessed7/1/2016.
48. Huntington Study Group, Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016; 316(1): 40-50.
49. Anderson KE, Factor SA, Hauser RA, et al. A randomized, doubleblind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD). Poster presented at: The American Psychiatric Association Annual Meeting; May 14-18, 2016; Atlanta, GA.
50. Yao Z, Wei X, Wu X, et al. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur J Med Chem. 2011; 46(5): 1841-1848.
51. O'Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015; 30(12): 1681-1687.
52. Josiassen RC, Remington G, Burke J, et al. Valbenazine (NBI-98854) is effective for treating tardive dyskinesia in individuals with schizophrenia or mood disorder. Poster presented at: The American Psychiatric Association Annual Meeting; May 14-18, 2016; Atlanta, GA.
53. Marder S, Knesevich MA, Hauser RA, et al. KINECT 3: a randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia. Poster presented at: The American Psychiatric Association Annual Meeting; May 14-18, 2016; Atlanta, GA.
54. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011; 45(4): 525-531.